CardiaLen

company

About

CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$2.80M
Industries
Biotechnology,Life Science,Medical Device
Founded date
Jan 1, 2008
Number Of Employee
11 - 50
Operating Status
Active

CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition.

It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$4.32M
CardiaLen has raised a total of $4.32M in funding over 2 rounds. Their latest funding was raised on Jan 19, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 19, 2021 Grant $2.80M 1 National Institutes of Health Detail
Mar 26, 2015 Series B $1.52M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
CardiaLen is funded by 2 investors. National Institutes of Health and Twin Cities Angels are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Twin Cities Angels Series B